Anika Therapeutics, Inc. (ANIK)
21.55
+0.44
(+2.08%)
USD |
NASDAQ |
Sep 02, 16:00
Anika Therapeutics Research and Development Expense (Annual) : 25.77M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 25.77M |
| December 31, 2024 | 25.54M |
| December 31, 2023 | 21.76M |
| December 31, 2022 | 28.18M |
| December 31, 2021 | 26.73M |
| December 31, 2020 | 22.02M |
| December 31, 2019 | 16.66M |
| December 31, 2018 | 18.19M |
| December 31, 2017 | 18.79M |
| December 31, 2016 | 10.73M |
| December 31, 2015 | 8.987M |
| December 31, 2014 | 8.144M |
| December 31, 2013 | 7.060M |
| December 31, 2012 | 5.388M |
| December 31, 2011 | 6.169M |
| December 31, 2010 | 6.875M |
| Date | Value |
|---|---|
| December 31, 2009 | 8.182M |
| December 31, 2008 | 7.399M |
| December 31, 2007 | 4.365M |
| December 31, 2006 | 3.616M |
| December 31, 2005 | 4.731M |
| December 31, 2004 | 4.087M |
| December 31, 2003 | 2.595M |
| December 31, 2002 | 3.928M |
| December 31, 2001 | 4.280M |
| December 31, 2000 | 3.26M |
| December 31, 1999 | 4.154M |
| December 31, 1998 | 1.956M |
| December 31, 1997 | 1.958M |
| August 31, 1996 | 1.635M |
| August 31, 1995 | 1.318M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics, Inc. | 70.96M |
| MiMedx Group, Inc. | 14.70M |
| ABVC BioPharma, Inc. | 0.1211M |
| Enovis Corp. | 120.33M |
| Edwards Lifesciences Corp. | 1.079B |